期刊文献+

甲基化抑制剂对CEM细胞EphB4基因表达及细胞增殖与凋亡的影响

Effect of methylation inhibitor on EphB4 gene expression,proliferation and apoptosis in CEM cells
原文传递
导出
摘要 目的探讨甲基化抑制剂5-氮杂-2'-脱氧胞苷(5-aza-2'-deoxycytidine,5-aza-CdR)对人急性淋巴细胞白血病细胞株CEM中抑癌基因EphB4的转录调控作用及对CEM细胞增殖凋亡的生物学影响,为寻找肿瘤治疗新靶点提供实验依据。方法采用亚硫酸氢盐修饰后测序法检测EphB4基因甲基化水平,荧光定量PCR法(Q-PCR)和Western blot方法检测5-aza-CdR处理前后EphB4基因mRNA及蛋白表达水平;MTS法检测不同剂量(1.0、2.5、5.0μmol/L)的5-aza-CdR作用于CEM细胞0 h、24 h、48 h、72 h、96 h对CEM细胞存活率的影响,流式细胞仪分析5-aza-CdR作用96 h对CEM细胞周期及凋亡的影响。结果 CEM细胞中存在EphB4基因的甲基化,甲基化水平为31.4%;不同浓度5-aza-CdR作用后CEM细胞甲基化水平均下降。5-aza-CdR作用使CEM细胞中EphB4基因的mRNA和蛋白表达上升;5-aza-CdR明显抑制CEM细胞增殖,并与药物浓度及作用时间呈正相关。5-aza-CdR处理96 h后,早期凋亡由4.1%上升为24.8%。用药96 h后,CEM细胞G1期由62.4%降至46.8%,G2期由2.1%升至16.2%,细胞阻滞于G2期。结论特异性甲基化转移酶抑制剂5-aza-CdR能使CEM细胞中沉默的EphB4基因重新表达,并可抑制白血病细胞增殖和诱导其凋亡。 Objective To study the regulation of methylation inhibitor 5-aza-2′-deoxycytidine on transcription of EphB4 gene and effects on the proliferation and apoptosis of human acute lymphocyte leukemia cell line CEM. Methods Bisulfite sequencing PCR was used to detect CpG island methylation density in EphB4 promoter.The expression of EphB4 mRNA and protein was determined by Q-PCR and Western blot.MTS assay and flow cytometry were used to detect the apoptosis of CEM cells after treatment with different concentrations of 5-aza-2′-deoxycytidine(1.0,2.5 and 5 μmol/L). Results Methylation of EphB4 gene promoter was detected in CEM cells(31.4%).The methylation level of EphB4 gene was down-regulated after treatment with various concentrations of 5-aza-2′-deoxycytidine.The EphB4 mRNA and protein expression in CEM cells increased after 5-aza-2′-deoxycytidine treatment.5-Aza-2′-deoxycytidine significantly inhibited the cell growth in dose and time dependent manners.Early apoptosis rates of CEM cells increased from 4.1% to 24.8% 96 hrs after 5-aza-2′-deoxycytidine treatment.CEM cells in G1 phase decreased from 62.4% to 46.8%,cells in G2 phase increased from 2.1% to 16.2%,and CEM cells were arrested in G2 phase after treatment with 5 μmol/L 5-aza-2′-deoxycytidine for 96 hrs. Conclusions 5-Aza-2′-deoxycytidine,an inhibitor of specific methylation transferase,can induce expression of the silent EphB4 gene in CEM cells,inhibit the proliferation of leukemia cells and induce cell apoptosis.
出处 《中国当代儿科杂志》 CAS CSCD 北大核心 2012年第3期205-209,共5页 Chinese Journal of Contemporary Pediatrics
基金 广东省自然科学基金(No.S2011010004349) 深圳市科技计划项目(No.201102156)
关键词 5-氮杂-2'-脱氧胞苷 EphB4基因 增殖 凋亡 CEM细胞 5-Aza-2′-deoxycytidine EphB4 gene Proliferation Apotosis CEM cell
  • 相关文献

参考文献12

  • 1李玉华,文飞球.DNA甲基化与儿童白血病的临床研究进展[J].中国当代儿科杂志,2011,13(2):174-176. 被引量:3
  • 2Batlle E,Bacani J,Begthel H,Jonkeer S,Gregorieff A,van deBorn M,et al.EphB receptor activity suppresses colorectal cancerprogression[J].Nature,2005,435(7045):1126-1130.
  • 3Noren NK,Foos G,Hauser CA,Pasquale EB.The EphB4 recep-tor suppresses breast cancer cell tumorigenicity through an Abl-Crkpathway[J].Nat Cell Biol,2006,8(8):815-825.
  • 4Alazzouzi H,Davalos V,Kokko A,Domingo E,Woerner SM,Wilson AJ,et al.Mechanisms of inactivation of the receptor tyro-sine kinase EPHB2 in colorectal tumors[J].Cancer Res,2005,65(22):10170-10173.
  • 5Davalos V,Dopeso H,Castan~o J,Wilson AJ,Vilardell F,Rome-ro-Gimenez J,et al.EPHB4 and survival of colorectal cancer pa-tients[J].Cancer Res,2006,66(18):8943-8948.
  • 6Fox BP,Kandpal RP.Transcriptional silencing of EphB6 receptortyrosine kinase in invasive breast carcinoma cells and detection ofmethylated promoter by methylation specific PCR[J].BiochemBiophys Res Commun,2006,340(1):268-276.
  • 7Guo H,Miao H,Gerber L,Singh J,Denning MF,Gilliam AC,et al.Disruption of EphA2 receptor tyrosine kinase leads to in-creased susceptibility to carcinogenesis in mouse skin[J].CancerRes,2006,66(14):7050-7058.
  • 8Huusko P,Ponciano-Jackson D,Wolf M,Kiefer JA,Azorsa DO,Tuzmen S,et al.Nonsense-mediated decay microarray analysisidentifies mutations of EPHB2 in human prostate cancer[J].NatGenet,2004,36(9):979-983.
  • 9Kuang SQ,Tong WG,Yang H,Lin W,Lee MK,Fang ZH,etal.Genome-wide identification of aberrantly methylated promoterassociated CpG islands in acute lymphocytic leukemia[J].Leuke-mia,2008,22(8):1529-1538.
  • 10Egger G,Liang G,Aparicio A,Jones PA.Epigenetics in humandisease and prospects for epigenetic therapy[J].Nature,2004,429(6990):457-463.

二级参考文献31

  • 1Wang Y, Leung FC. An evaluation of new criteria for CpG islands in the human genome as gene markers[J]. Bioinformatics, 2004, 20(7): 1170-1177.
  • 2Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics[J]. Nat Rev Genet, 2008, 9(6): 465-476.
  • 3Greaves M. In utero origins of childhood leukaemia[J]. Early Hum Dev, 2005, 81(1): 123-129.
  • 4Conrad B, Antonarakis SE. Gene duplication: A drive for phenotypic diversity and cause of human disease[J]. Annu Rev Genomics Hum Genet, 2007, 8: 17-35.
  • 5Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer[J]. Nat Rev Genet, 2006, 7(1): 21-33.
  • 6Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Navarro G, Garate L, et al. Promoter hypermethylation and global hypomethylation are independent epigenetic events in lymphoid leukemogenesis with opposing effects on clinical outcome[J]. Leukemia, 2006, 20(8): 1445-1448.
  • 7Davidsson J, Lilljebjorn H, Andersson A, Veerla S, Heldrup J, Behrendtz M, et al. The DNA methylome of pediatric acute lymphoblastic leukemia[J]. Hum Mol Genet, 2009, 18(21): 4054-4065.
  • 8Flotho C, Paulun A, Batz C, Niemeyer CM. AKAP12, a gene with tumour suppressor properties, is a target of promoter DNA methylation in childhood myeloid malignancies[J]. Br J Haematol, 2007, 138(5): 644-650.
  • 9Stam RW, den Boer ML, Passier M, Janka-Schaub GE, Sallan SE, Armstrong SA, et al. Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia[J]. Leukemia, 2006, 20(2): 264-271.
  • 10Stumpel DJ, Schneider P, van Roon EH, Boer JM, de Lorenzo P, Valsecchi MG, et al. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options[J]. Blood, 2009, 114(27): 5490-5498.

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部